SciClone Files China BLA for Neuroblastoma Treatment

SciClone Pharma, a  Shanghai in-licensing company, filed a China BLA for Danylza® to treat high-risk neuroblastoma. In late 2020, SciClone announced a $120 million agreement to acquire China rights for two neuroblastoma therapies from New York 's Y-mAbs. In the US , Danylza® is approved to treat pediatric patients 1 year of age and older along with adult patients who have relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Danylza® is administered along with granulocyte-macrophage colony-stimulating factor (GM-CSF). More details.... Stock Symbol: (HK: 6600) Share this with colleagues: // //